Item 2.02 Results of Operations and Financial Condition.
On July 29, 2021, Emergent BioSolutions Inc. (the "Company") announced financial
and operating results for the three- and six-month periods ended June 30, 2021.
The Company will also use presentation materials in connection with the
conference call scheduled for the same day to discuss these results ("Earnings
Call Slides"). Such presentation materials will be posted on the Company's
website at www.emergentbiosolutions.com. Copies of the earnings press release
and Earnings Call Slides are furnished as Exhibit 99.1 and Exhibit 99.2 to this
Current Report on Form 8-K, respectively, and are incorporated herein by
Item 7.01 Regulation FD Disclosure.
The disclosure contained in Item 2.02 of this Current Report on Form 8-K is
incorporated herein by reference.
Item 8.01 Other Events.
Also on July 29, 2021, the Company issued a press release announcing that the
U.S. Food and Drug Administration is allowing the Company's Bayview
manufacturing facility to resume production of Johnson & Johnson's Covid-19
vaccine bulk drug substance. A copy of that press release is attached hereto as
Exhibit 99.3 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description
99.1 Earnings P ress release issued by the Company on July 29, 2021.
99.2 Earnings Call Slides, dated July 29, 2021.
99.3 Press release issued by the Company on July 29, 2021.
Emergent BioSolutions Inc. Current Report on Form 8-K, dated July 29,
101 2021 formatted in XBRL (Extensible Business Reporting Language): Cover
Page. The instance document does not appear in the Interactive Data File
because its XBRL tags are embedded within the Inline XBRL document.
Cover Page Interactive Data File (formatted as Inline XBRL and contained
104 in Exhibit 101).
© Edgar Online, source Glimpses